Literature DB >> 7899988

Recurrence of spinal ependymoma. Risk factors and long-term survival.

L Cervoni1, P Celli, A Fortuna, G Cantore.   

Abstract

STUDY
DESIGN: A study was conducted on 78 patients with spinal ependymoma. The authors divided the patients in two groups.
OBJECTIVES: The aim was to elicit the risk factors for recurrence and the fate of patients who underwent second operations. SUMMARY OF BACKGROUND DATA: Group A is made up of 59 patients with no signs of recurrence at follow-up (median 14 years), and group B is made up of 19 patients who had undergone second operations because of relapses (follow-up median 12 years).
METHODS: The clinical and therapeutic characteristics and survival of the two groups were compared statistically. RESULT: Analysis of the series shows that the most important points in predicting recurrence are length of clinical history (P < 0.05), gross appearance of the tumor at first operation (P < 0.05), and type of excision (P < 0.001).
CONCLUSION: These factors proved to be closely interrelated. In the event of recurrence, spinal ependymoma has an adverse prognosis.

Entities:  

Mesh:

Year:  1994        PMID: 7899988     DOI: 10.1097/00007632-199412150-00019

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  10 in total

1.  Histologic grade and extent of resection are associated with survival in pediatric spinal cord ependymomas.

Authors:  Michael Safaee; Michael C Oh; Joseph M Kim; Derick Aranda; Phiroz E Tarapore; Tene A Cage; Nalin Gupta; Andrew T Parsa
Journal:  Childs Nerv Syst       Date:  2013-05-16       Impact factor: 1.475

2.  Recurrence from filum terminale ependymoma 42 years after 'total' removal and radiotherapy.

Authors:  P Celli; L Cervoni; M Salvati; G Cantore
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

3.  High failure rate in spinal ependymomas with long-term follow-up.

Authors:  Daniel R Gomez; Brian T Missett; William M Wara; Kathleen R Lamborn; Michael D Prados; Susan Chang; Mitchel S Berger; Daphne A Haas-Kogan
Journal:  Neuro Oncol       Date:  2005-07       Impact factor: 12.300

4.  Adjuvant radiotherapy delays recurrence following subtotal resection of spinal cord ependymomas.

Authors:  Michael C Oh; Michael E Ivan; Matthew Z Sun; Gurvinder Kaur; Michael Safaee; Joseph M Kim; Eli T Sayegh; Derick Aranda; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2012-12-09       Impact factor: 12.300

Review 5.  Prognosis by tumor location in adults with intracranial ependymomas.

Authors:  Eli T Sayegh; Derick Aranda; Joseph M Kim; Taemin Oh; Andrew T Parsa; Michael C Oh
Journal:  J Clin Neurosci       Date:  2014-07-15       Impact factor: 1.961

6.  Primary spinal cord glioma: a Surveillance, Epidemiology, and End Results database study.

Authors:  Michael T Milano; Mahlon D Johnson; Joohee Sul; Nimish A Mohile; David N Korones; Paul Okunieff; Kevin A Walter
Journal:  J Neurooncol       Date:  2009-11-07       Impact factor: 4.130

7.  Spinal ependymomas: benefits of extent of resection for different histological grades.

Authors:  Michael C Oh; Phiroz E Tarapore; Joseph M Kim; Matthew Z Sun; Michael Safaee; Gurvinder Kaur; Derick M Aranda; Andrew T Parsa
Journal:  J Clin Neurosci       Date:  2013-06-12       Impact factor: 1.961

8.  Surgical considerations of spinal ependymomas in the pediatric population.

Authors:  Wesley Hsu; Gustavo Pradilla; Shlomi Constantini; George I Jallo
Journal:  Childs Nerv Syst       Date:  2009-04-10       Impact factor: 1.475

9.  Long term outcome with post-operative radiation therapy for spinal canal ependymoma.

Authors:  Sasha H Wahab; Joseph R Simpson; Jeff M Michalski; David B Mansur
Journal:  J Neurooncol       Date:  2007-01-06       Impact factor: 4.506

10.  Predictors of Functional Outcome after Spinal Ependymoma Resection.

Authors:  Ivan Domazet; Ivan Pašalić; Jakob Nemir; Vjerislav Peterković; Miroslav Vukić
Journal:  J Neurosci Rural Pract       Date:  2018 Jul-Sep
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.